Confidence to Treat Every Patient, Any Challenge

Modern PCI means using all the newest data and tools at our disposal to provide the best possible treatment for coronary artery disease (CAD) patients. The latest SYNTAX II results, along with supporting clinical evidence, show that integrating risk stratification, multidisciplinary collaboration, new tools & techniques, and innovative drug eluting stent (DES) can lead to better outcomes -- even in the most complex cases.

 

Pooled analysis from the HORIZONS-AMI1 and ACUITY TRIALS1 demonstrates that calcium creates worse clinical outcomes if not treated appropriately, replace with: and increasing severity of calcium is directly tied to higher rates of MACE, TLR and MI. It also suggests that as many as 30% of patients have moderate to severe calcium, who may benefit from atherectomy to achieve optimal outcomes.

Moderate to severe lesion calcification was relatively frequent and strongly predictive of stent thrombosis and ischemic TLR at 1 year.


The SYNTAX II trial demonstrated that rotablation for the preparation of severely calcified lesions is associated with a superior acute success rate compared to standard or modified balloons.
 
Better acute lumen gain,  No excessive lumen loss, Excellent clinical outcomes in PREPARE-CALC,  More pronounced clinical benefit of DES 
 
 
ROTAPRO
Learn how ROTAPRO will combat calcium to improve your patients' outcomes but speed up your case.
 

 
The SYNTAX Score II is a foundational element of the SYNTAX II trial. It is a tool to measure the complexity of coronary artery disease in an individual patient and ultimately create a highly personalized, patient-centric treatment recommendation.  
 
 
 

Regardless of patient complexity, excellent long term outcomes out to 5 years are achievable when following the SYNTAX II approach.



 
The CONSISTENT CTO2 study showed the use of up-to-date technologies and techniques in opening a CTO, including the use of an everolimus eluting stent with a bioabsorbable polymer, can result in significant quality of life improvements without significant impact on intravascular healing, even in very symptomatic patients with complex lesions.  
 
 
SYNTAX II3 examined the outcomes of a PCI strategy focused on utilizing the newest data and tools to provide the best possible treatment for CAD patients. Among the modern tools used in the trial was Boston Scientific’s SYNERGY Bioabsorbable Polymer (BP) Stent Platform. At the five-year milestone, the trial has demonstrated CABG-like outcomes through modern PCI.
 

 
Low rates of revascularization, peri-procedural MI, and acute ST suggest that superior tools might help reduce procedure-related complications in multi-vessel diseased patients.

SYNERGY’s Everolimus drug and bioabsorbable polymer promote early healing through fast drug elution and freedom from the risks of long-term polymer exposure.


SYNERGY MEGATRON

SYNERGY MEGATRON

Meet the newest member of the SYNERGY stent family – now transforming large vessel PCI. 
SYNERGY MEGATRON
Stent deformation, which is associated with major adverse cardiac events, is present in nearly 7% of cases4. SYNERGY MEGATRON offers maximum axial & radial strength with the largest overexpansion range and uniform scaffolding capabilities to optimize your large vessel PCI.
 

Get exclusive product updates, training and educational opportunities, and more. 

Fill out a quick form and one of our sales representatives will be in touch. 
Top